About the Company
kalobios is a biopharmaceutical company dedicated to helping the lives of patients with innovative therapies. our mission is to improve the lives of cancer patients with innovative, humaneered®, monoclonal antibodies. kalobios' humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today's marketed antibody products. using our expertise, our antibodies are customized to enhance a desired effect or reduce a possible undesired effect. our pipeline is comprised of humaneered® antibodies. these antibodies are being investigated in clinical development programs focused on treating cancer: kb004 (anti-epha3) humaneered® mab to treat patients with hematologic malignancies, solid tumors, and their stem cells; currently enrolling patients with myelofibrosis and myelodysplastic syndrome in the company’s phase 2 expansion portion of its phase 1/2 clinical trial in hematologic malignancies; and kb003 (anti-gm-csf) humaneered® mab that kal
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $HGEN News
Humanigen Inc HGENQ
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
HGEN Stock Alert: Why Humanigen Just Filed for Ch. 11 Bankruptcy
Humanigen (OTCMKTS:HGEN) stock is falling hard on Friday after the company filed for Chapter 11 bankruptcy protection. This ...
Humanigen's COVID-19 Candidate Shows 2.5 Fold Increase In Survival Without Ventilation
Humanigen Inc (NASDAQ: HGEN) has announced an analysis of results from its Phase 3 LIVE-AIR study of lenzilumab in hospitalized patients with COVID-19. Data suggested that Black and African ...
Levi & Korsinsky, LLP Notifies Shareholders of Humanigen, Inc. (HGEN) an Upcoming Claims Deadline in a Class Action Settlement
NEW YORK, NY / ACCESSWIRE / February 29, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Humanigen, Inc. (NASDAQ:HGEN). The ...
Eyeing emergency use of COVID-19 drug, Humanigen partners with Lonza to make it
Humanigen is hoping for emergency use authorisation in the US for an antibody to treat severe COVID-19 before the end of 2020, and has teamed up with Swiss contract manufacturer Lonza to make sure ...
Humanigen and Cenexi Announce Collaboration to Manufacture Lenzilumab in France
BURLINGAME, Calif. & FONTENAY-SOUS-BOIS, France--(BUSINESS WIRE)-- Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company ...
Humanigen Announces Ken Trbovich Appointed as Senior Vice President, Investor Relations
Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead ...
Humanigen Launches Managed Access Program for Lenzilumab
BURLINGAME, Calif. & DUBLIN & LONDON--(BUSINESS WIRE)-- Humanigen, Inc. (Nasdaq: HGEN), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response ...
Carisma Therapeutics Announces Changes to its Board of Directors
Inc., Humanigen, Inc. and Aravive, Inc. Dr. Hohneker received his bachelor's degree in chemistry from Gettysburg College and his M.D. from the Rutgers School of Biomedical and Health Sciences ...
Direxion Daily S&P Biotech Bull 3X Shares (ARCA:LABU), Quotes and News Summary
Mark Putrino This Biotech Stock Could See A Big Move If It Breaks Out Of The Pennant It's Forming Humanigen Inc. (NASDAQ: HGEN) shares made gains Wednesday following the publication of results ...
About Inc.com | Everything You Need to Know to Grow and Start Your Business
Inc. is the voice of the American entrepreneur. We inspire, inform, and document the most fascinating people in business: the risk-takers, the innovators, and the ultra-driven go-getters that ...
Humanigen Inc
*Each quarterly filing is treated as a separate report. Feel free to distribute or cite this material, but please credit OpenSecrets. For permission to reprint for commercial uses, such as textbooks, ...
Loading the latest forecasts...